Abstract 1707
Background
While atezolizumab, an anti-PD-L1 monoclonal antibody, is clinically effective against non-small cell lung cancer (NSCLC), its immunological effects on the tumor microenvironment (TME) have not been fully clarified.
Methods
For the biomarker analyses, tumor samples were obtained at baseline, 6 weeks after the initiation of therapy, and/or at the end of therapy. Tumor-infiltrating lymphocytes (TILs) were extracted from those tumor specimens and were subjected to flow cytometry and/or CyTOF for detailed immune profiling.
Results
Twenty-seven eligible patients were analyzed in this trial. The preliminary efficacy results showed an overall RR of 19%, a DCR of 63%, and a median PFS of 4.1 months. To elucidate biomarkers, we compared the immune profiling results between 8 responders (CR, PR, or SD ≥ 6 weeks) and 18 non-responders (SD < 6 weeks or PD). There was no significant difference in the frequency of CD8+ T cells (42.6%±5.3% vs. 38.6%±3.5%, P = 0.53) or that of CD45RA-FoxP3highCD4+ regulatory T cells (Tregs) (14.6%±3.9% vs. 15.4%±2.1%, P = 0.85) at baseline between responders and non-responders. In the responders, PD-1 expression by CD8+TILs was significantly higher than in the non-responders (51.7%±4.7% vs. 25.1%±3.6%, P < 0.01). In addition, PD-1 expression by CD8+TILs increased after atezolizumab therapy regardless of the efficacy of this treatment (P < 0.01), whereas that by Tregs in TILs was comparable (P = 0.76). In addition, we conducted genomic analysis, molecular expression assessment and CyTOF profiling to detect biomarker for atezolizumab.
Conclusions
PD-1 expression by CD8+TILs could be a predictive biomarker for the efficacy of PD-1/PD-L1 blockade therapies. Atezolizumab increased PD-1 expression by CD8+T cells but not by Treg cells in TILs, suggesting that atezolizumab can activate CD8+T cells but not Treg cells in the TME.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center Hospital.
Funding
Chugai Pharma.
Disclosure
K. Kirita: Honoraria (self), Research grant / Funding (institution): Chugai Pharma; Honoraria (self): AstraZeneca; Honoraria (self): Novartis; Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (self): MSD Oncology. Y. Togashi: Honoraria (self): Chugai Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Ono Pharmaceutical; Honoraria (self): MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Brystol-Myers Squibb. H. Udagawa: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AbbVie; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Honoraria (self): AstraZeneca; Honoraria (self): Chugai Pharma; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (self): Daiichi Sankyo; Research grant / Funding (self): Amgen. S. Nomura: Honoraria (self): Taiho Pharmaceutical. Y. Zenke: Honoraria (self): Boehringer Ingelheim; Honoraria (self): Chugai Pharma; Honoraria (self): AstraZeneca; Honoraria (self): Lilly; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): MSD Oncology; Research grant / Funding (institution): Ono Pharmaceutical. S. Matsumoto: Honoraria (self), Research grant / Funding (institution): Ono pharmaceutical; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Japan; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): AstraZeneca KK; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Kyowa Hakko Kirin; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Riken Genesis; Research grant / Funding (institution): MSD. K. Yoh: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly Japan; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Honoraria (self): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self): Kirin Pharmaceuticals; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Ono Pharmaceutical. S. Niho: Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self): Ono Pharmaceutival; Research grant / Funding (institution): Merck Serono. A. Sato: Honoraria (self), Research grant / Funding (institution): Sumitomo Dainippon Pharma; Honoraria (self): AstraZeneca; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Oncolys BioPharma; Research grant / Funding (institution): Aspyerian Therapeutics. H. Nishikawa: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (self): Bristol-Myers Squibb Japan; Honoraria (self), Research grant / Funding (self): Chugai Pharma; Research grant / Funding (self): BD Biosciences; Research grant / Funding (self): Daiichi Sankyo; Research grant / Funding (self): Kyowa Hakko Kirin; Research grant / Funding (self): Zenyaku Kogyo; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Astellas Pharma; Research grant / Funding (self): Taiho Pharmaceutical; Research grant / Funding (self): Asahi Kasei; Research grant / Funding (self): Sysmex. K. Goto: Honoraria (self), Advisory / Consultancy: Otsuka; Honoraria (self), Research grant / Funding (self): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self), Research grant / Funding (self): Chugai Pharma; Honoraria (self), Research grant / Funding (self): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (self): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (self): Novartis; Honoraria (self), Research grant / Funding (self): Lilly; Honoraria (self), Research grant / Funding (self): Boehringer Ingelheim; Honoraria (self): Quintiles; Honoraria (self), Research grant / Funding (self): Merck Serono; Honoraria (self), Research grant / Funding (self): Life Technologies; Honoraria (self), Research grant / Funding (self): MSD; Honoraria (self): AbbVie; Honoraria (self), Research grant / Funding (self): Riken Genesis; Honoraria (self): Nippon Kayaku; Honoraria (self), Research grant / Funding (self): Takeda; Honoraria (self): SRL Diagnostics; Research grant / Funding (self): Sumitomo Dainippon Pharma. All other authors have declared no conflicts of interest.
Resources from the same session
2036 - Salivary metabolomics for colorectal cancer detection
Presenter: Hiroshi Kuwabara
Session: Poster Display session 3
Resources:
Abstract
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract